Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)

NCT01135056 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT01135056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01135056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Lead sponsor
Singapore General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2010
Completion date
July 31, 2018
Enrollment
360 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma